Smartlens is a clinical-stage medical technology company with a vision of preventing blindness due to Glaucoma.
Beginning as an academic research at Stanford University, Smartlens has developed ultra-sensitive, electronics-free and affordable soft contact lenses capable of measuring intraocular pressure (IOP), the primary and only modifiable risk factor of Glaucoma.
As the leading cause of irreversible blindness worldwide, Glaucoma (a.k.a. silent thief of sight) is a group of eye diseases that are very difficult to diagnose, treat, and monitor. More than 50% of the people suffering from Glaucoma are undiagnosed. Patients who are already diagnosed and comply with the treatment get their IOP measured at the clinic once every 3-4 months.
Our contact lens can significantly improve patient outcomes and how doctors manage the disease by providing an efficient and convenient way of monitoring IOP anywhere at any time. With our strong IP, we have the unique opportunity to intervene and prevent Glaucoma-related blindness.
At Smartlens, we envision a world where Glaucoma can’t rob people of their vision and quality of life.